Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Wan-Ling Liu, Yong-Qu Zhang, Xiang-Jie Luo, Yuan-Yuan Zhu, Liang Song, Zi-He Ming, Li-Xin Zhang, Meng-Jun Li, Rui-Chan Lv, Guo-Jun Zhang & Min Chen. (2023) Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer. International Journal of Nanomedicine 18, pages 5141-5157.
Read now
Read now
Ioannis M. Koukourakis, Dina Tiniakos, Vassilis Kouloulias & Anna Zygogianni. (2023) The molecular basis of immuno-radiotherapy. International Journal of Radiation Biology 99:5, pages 715-736.
Read now
Read now
Kim Cao, Louisa Abbassi, Emanuela Romano & Youlia Kirova. (2021) Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives. Expert Review of Anticancer Therapy 21:5, pages 501-510.
Read now
Read now
James CH Chow, Roger KC Ngan, KM Cheung & William CS Cho. (2019) Immunotherapeutic approaches in nasopharyngeal carcinoma. Expert Opinion on Biological Therapy 19:11, pages 1165-1172.
Read now
Read now
Kirtesh R. Patel, Anthony Martinez, John M. Stahl, Suzanna J. Logan, Adam J. Perricone, Matthew J. Ferris, Zachary S. Buchwald, Mudit Chowdhary, Keith A. Delman, David K. Monson, Shervin V. Oskouei, Nicholas B. Reimer, Kenneth Cardona, Mark A. Edgar & Karen D. Godette. (2018) Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. OncoImmunology 7:7.
Read now
Read now
Abhishek D. Garg, Sanket More, Nicole Rufo, Odeta Mece, Maria Livia Sassano, Patrizia Agostinis, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2017) Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. OncoImmunology 6:12.
Read now
Read now
Erika Vacchelli, Norma Bloy, Fernando Aranda, Aitziber Buqué, Isabelle Cremer, Sandra Demaria, Alexander Eggermont, Silvia Chiara Formenti, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2016) Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology 5:9.
Read now
Read now
Articles from other publishers (59)
Zhen Yu, Yuying Hao, Yuhua Huang, Ling Ling, Xigang Hu & Simiao Qiao. (2023) Radiotherapy in the preoperative neoadjuvant treatment of locally advanced rectal cancer. Frontiers in Oncology 13.
Crossref
Crossref
Ioannis M. Koukourakis, Erasmia Xanthopoulou, Theologos I. Sgouras, Maria Kouroupi, Alexandra Giatromanolaki, Vassilios Kouloulias, Dina Tiniakos & Anna Zygogianni. (2023) Preoperative chemoradiotherapy induces multiple pathways related to anti-tumour immunity in rectal cancer. British Journal of Cancer 129:11, pages 1852-1862.
Crossref
Crossref
Juefeng Wan, Ruiyan Wu, Miaomiao Fu, Lijun Shen, Hui Zhang, Yan Wang, Yaqi Wang, Shujuan Zhou, Yajie Chen, Fan Xia & Zhen Zhang. (2023) TORCH-R trial protocol: hypofractionated radiotherapy combined with chemotherapy and toripalimab for locally recurrent rectal cancer: a prospective, single-arm, two-cohort, phase II trial. Frontiers in Oncology 13.
Crossref
Crossref
Hsuan‐Chen Liu, Simone Capuani, Andrew A. Badachhape, Nicola Di Trani, Daniel Davila Gonzalez, Robin S. Vander Pol, Dixita I. Viswanath, Shani Saunders, Nathanael Hernandez, Ketan B. Ghaghada, Shu‐Hsia Chen, Elizabeth Nance, Ananth V. Annapragada, Corrine Ying Xuan Chua & Alessandro Grattoni. (2023) Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer. Bioengineering & Translational Medicine 8:6.
Crossref
Crossref
Arta M. Monjazeb, Megan E. Daly, Guillaume Luxardi, Emanual Maverakis, Alexander A. Merleev, Alina I. Marusina, Alexander Borowsky, Amin Mirhadi, Stephen L. Shiao, Laurel Beckett, Shuai Chen, David Eastham, Tianhong Li, Logan V. Vick, Heather M. McGee, Frances Lara, Leslie Garcia, Leigh Anne Morris, Robert J. Canter, Jonathan W. Riess, Kurt A. Schalper, William J. Murphy & Karen Kelly. (2023) Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial. Nature Communications 14:1.
Crossref
Crossref
A. Camps Maléa, C. Hennequin & S. Rivera. (2023) Traitements systémiques ciblés et radiothérapie locorégionale pour les cancers du sein : peut-on espérer un bénéfice de la potentialisation du traitement local ?. Cancer/Radiothérapie.
Crossref
Crossref
Jianfeng Peng, Xiaoyan Yin, Wenhua Yun, Xiangjiao Meng & Zhaoqin Huang. (2023) Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance. Cancer Letters 559, pages 216108.
Crossref
Crossref
Rong Zheng, Bi-Si Wang, Zhihua Li, Pan Chi & Benhua Xu. (2023) Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial. BMJ Open 13:3, pages e066976.
Crossref
Crossref
Xiaoqin Ji, Wanrong Jiang, Jiasheng Wang, Bin Zhou, Wei Ding, Shuling Liu, Hua Huang, Guanhua Chen & Xiangdong Sun. (2023) Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. Frontiers in Immunology 13.
Crossref
Crossref
Céline Mirjolet, Jérémy Baude & Lorenzo Galluzzi. 2023. Ionizing Radiation and the Immune Response - Part B. Ionizing Radiation and the Immune Response - Part B
xiii
xxiv
.
Yaqi Wang, Lijun Shen, Juefeng Wan, Hui Zhang, Ruiyan Wu, Jingwen Wang, Yan Wang, Ye Xu, Sanjun Cai, Zhen Zhang & Fan Xia. (2022) Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH). BMC Cancer 22:1.
Crossref
Crossref
Laurel B. Darragh, Michael M. Knitz, Junxiao Hu, Eric T. Clambey, Jennifer Backus, Andrew Dumit, Von Samedi, Andrew Bubak, Casey Greene, Timothy Waxweiler, Sanjana Mehrotra, Shilpa Bhatia, Jacob Gadwa, Thomas Bickett, Miles Piper, Kareem Fakhoury, Arthur Liu, Joshua Petit, Daniel Bowles, Ashesh Thaker, Kimberly Atiyeh, Julie Goddard, Robert Hoyer, Adrie Van Bokhoven, Kimberly Jordan, Antonio Jimeno, Angelo D’Alessandro, David Raben, Jessica D. McDermott & Sana D. Karam. (2022) A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nature Cancer 3:11, pages 1300-1317.
Crossref
Crossref
Edward Nabrinsky, Jason Macklis & Jacob Bitran. (2022) A Review of the Abscopal Effect in the Era of Immunotherapy. Cureus.
Crossref
Crossref
Icro Meattini, Lorenzo Livi, Nicla Lorito, Carlotta Becherini, Marina Bacci, Luca Visani, Alessandra Fozza, Liliana Belgioia, Mauro Loi, Monica Mangoni, Matteo Lambertini & Andrea Morandi. (2022) Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside. Cancer Treatment Reviews 108, pages 102417.
Crossref
Crossref
Danyi Zhai, Dandan An, Chao Wan & Kunyu Yang. (2022) Radiotherapy: Brightness and darkness in the era of immunotherapy. Translational Oncology 19, pages 101366.
Crossref
Crossref
Xianlan Zhao, Jixi Li, Linpeng Zheng, Qiao Yang, Xu Chen, Xiewan Chen, Yongxin Yu, Feng Li, Jianxiong Cui & Jianguo Sun. (2022) Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non–Small-Cell Lung Cancer. Frontiers in Molecular Biosciences 9.
Crossref
Crossref
Eva Reijmen, Sven De Mey, Wout De Mey, Thierry Gevaert, Kirsten De Ridder, Hanne Locy, Sandrina Martens, Emmy De Blay, Luc Bouwens, Pieterjan Debie, Karine Breckpot, Jacques De Grève, Mark De Ridder & Cleo Goyvaerts. (2021) Fractionated Radiation Severely Reduces the Number of CD8+ T Cells and Mature Antigen Presenting Cells Within Lung Tumors. International Journal of Radiation Oncology*Biology*Physics 111:1, pages 272-283.
Crossref
Crossref
Zachary S. Buchwald & Nicole C. Schmitt. (2021) Immunotherapeutic Strategies for Head and Neck Cancer. Otolaryngologic Clinics of North America 54:4, pages 729-742.
Crossref
Crossref
Hsuan-Chen Liu, Dixita I. Viswanath, Federica Pesaresi, Yitian Xu, Licheng Zhang, Nicola Di Trani, Jesus Paez-Mayorga, Nathanael Hernandez, Yu Wang, Donald R. Erm, Jeremy Ho, Antonia Susnjar, Xuewu Liu, Sandra Demaria, Shu-Hsia Chen, Bin S. Teh, Edward Brian Butler, Corrine Ying Xuan Chua & Alessandro Grattoni. (2021) Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1. International Journal of Radiation Oncology*Biology*Physics 110:2, pages 492-506.
Crossref
Crossref
Daniel R. Principe, Murray Korc, Suneel D. Kamath, Hidayatullah G. Munshi & Ajay Rana. (2021) Trials and tribulations of pancreatic cancer immunotherapy. Cancer Letters 504, pages 1-14.
Crossref
Crossref
Rebecca M. O’Brien, Aoife Cannon, John V. Reynolds, Joanne Lysaght & Niamh Lynam-Lennon. (2021) Complement in Tumourigenesis and the Response to Cancer Therapy. Cancers 13:6, pages 1209.
Crossref
Crossref
Adrien Procureur, Audrey Simonaggio, Jean-Emmanuel Bibault, Stéphane Oudard & Yann-Alexandre Vano. (2021) Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments. Cancers 13:4, pages 678.
Crossref
Crossref
Erminia Romano, Jamie Honeychurch & Timothy M. Illidge. (2021) Radiotherapy–Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery?. Cancers 13:3, pages 457.
Crossref
Crossref
Li Wang & Steven J. Frank. 2021. Proton Therapy. Proton Therapy
1
13.e6
.
Lukas Käsmann, Chukwuka Eze, Julian Taugner, Olarn Roengvoraphoj, Maurice Dantes, Nina-Sophie Schmidt-Hegemann, Sanziana Schiopu, Claus Belka & Farkhad Manapov. (2020) Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiation Oncology 15:1.
Crossref
Crossref
M. M. Rosado & C. Pioli. (2020) Cancer-host battles: measures and countermeasures in radiation-induced caspase activation and tumor immunogenicity. Cellular & Molecular Immunology 17:10, pages 1022-1023.
Crossref
Crossref
Cyrus Chargari, Antonin Levy, Xavier Paoletti, Jean-Charles Soria, Christophe Massard, Ralph R. Weichselbaum & Eric Deutsch. (2020) Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. Clinical Cancer Research 26:18, pages 4723-4736.
Crossref
Crossref
Gishan Ratnayake, Simone Reinwald, Mark Shackleton, Maggie Moore, Mark Voskoboynik, Jeremy Ruben, Menno C. van Zelm, Di Yu, Rachel Ward, Robin Smith, Andrew Haydon & Sashendra Senthi. (2020) Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial. International Journal of Radiation Oncology*Biology*Physics 108:1, pages 150-156.
Crossref
Crossref
Suneel D. Kamath, Aparna Kalyan, Sheetal Kircher, Halla Nimeiri, Angela J. Fought, Al BensonIIIIII & Mary Mulcahy. (2020) Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. The Oncologist 25:5, pages e808-e815.
Crossref
Crossref
Chuanhui Han, Zhida Liu, Yunjia Zhang, Aijun Shen, Chunbo Dong, Anli Zhang, Casey Moore, Zhenhua Ren, Changzheng Lu, Xuezhi Cao, Chun-Li Zhang, Jian Qiao & Yang-Xin Fu. (2020) Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. Nature Immunology 21:5, pages 546-554.
Crossref
Crossref
Camilla Christensen, Lotte K. Kristensen, Maria Z. Alfsen, Carsten H. Nielsen & Andreas Kjaer. (2019) Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody. European Journal of Nuclear Medicine and Molecular Imaging 47:5, pages 1302-1313.
Crossref
Crossref
Antonella Borgatti, Erin B. Dickerson & Jessica Lawrence. (2019) Emerging therapeutic approaches for canine sarcomas: Pushing the boundaries beyond the conventional. Veterinary and Comparative Oncology 18:1, pages 9-24.
Crossref
Crossref
Gishan Ratnayake, Mihir Shanker, Kate Roberts, Robert Mason, Brett G. M. Hughes, Zarnie Lwin, Vikram Jain, Kenneth O'Byrne, Margot Lehman & Benjamin Chua. (2019) Prior or concurrent radiotherapy and nivolumab immunotherapy in non–small cell lung cancer. Asia-Pacific Journal of Clinical Oncology 16:1, pages 56-62.
Crossref
Crossref
L.M. Abbassi, K.I. Cao & Y.M. Kirova. (2020) Immunothérapie et radiothérapie dans la prise en charge du cancer du sein : rationnel et synthèse de la littérature sur les applications cliniques actuelles. Cancer/Radiothérapie 24:1, pages 73-80.
Crossref
Crossref
Chinthaka B. Samaranayake, Elizabeth McCaffrey, John Coucher, Margot Lehman, G. Tao Mai & Michelle A. Murphy. (2020) Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study. ERJ Open Research 6:1, pages 00189-2019.
Crossref
Crossref
Nicole C. Schmitt & Robert L. Ferris. 2020. Novel Therapies in Head and Neck Cancer: Beyond the Horizon. Novel Therapies in Head and Neck Cancer: Beyond the Horizon
117
142
.
Elena Garelli, Achim Rittmeyer, Paul Martin Putora, Markus Glatzer, Ralf Dressel & Stefan Andreas. (2019) Abscopal effect in lung cancer: three case reports and a concise review. Immunotherapy 11:17, pages 1445-1461.
Crossref
Crossref
Alexandra Giatromanolaki, Ioannis M. Koukourakis, Konstantina Balaska, Achilleas G. Mitrakas, Adrian L. Harris & Michael I. Koukourakis. (2019) Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis. Medical Oncology 36:9.
Crossref
Crossref
Emily B. Ehlerding, Hye Jin Lee, Todd E. Barnhart, Dawei Jiang, Lei Kang, Douglas G. McNeel, Jonathan W. Engle & Weibo Cai. (2019)
Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with
89
Zr–Df–Atezolizumab
. Bioconjugate Chemistry 30:5, pages 1434-1441.
Crossref
Crossref
Ruben S. A. Goedegebuure, Leonie K. de Klerk, Adam J. Bass, Sarah Derks & Victor L. J. L. Thijssen. (2019) Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?. Frontiers in Immunology 9.
Crossref
Crossref
Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew E. Hendifar & Richard Tuli. (2018) Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. Journal for ImmunoTherapy of Cancer 6:1.
Crossref
Crossref
S. Rieken & R. El Shafie. (2018) Kombinationen von Strahlen- und Immuntherapie für urologische TumorerkrankungenCombining radiotherapy with immunotherapy for urological malignancies. Der Urologe 57:11, pages 1309-1315.
Crossref
Crossref
Toan Pham, Sara Roth, Joseph Kong, Glen Guerra, Vignesh Narasimhan, Lloyd Pereira, Jayesh Desai, Alexander Heriot & Robert Ramsay. (2018) An Update on Immunotherapy for Solid Tumors: A Review. Annals of Surgical Oncology 25:11, pages 3404-3412.
Crossref
Crossref
Takeharu Ono, Koichi Azuma, Akihiko Kawahara, Tetsuro Sasada, Norikazu Matsuo, Tatsuyuki Kakuma, Hiroyuki Kamimura, Ririko Maeda, Chikayuki Hattori, Kotaro On, Kei Nagata, Fumihiko Sato, Shun-ich Chitose, Buichiro Shin, Takeichiro Aso, Jun Akiba & Hirohito Umeno. (2018) Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment. Head & Neck 40:9, pages 2007-2019.
Crossref
Crossref
Xu Shan Sun, Cécile Michel, Emmanuel Babin, Dominique De Raucourt, Adeline Péchery, Elisabeta Gherga, Bernard Géry, Carmen Florescu, Jean Bourhis & Juliette Thariat. (2018) Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC. Future Oncology 14:9, pages 877-889.
Crossref
Crossref
Yu Jin Lim, Jaemoon Koh, Sehui Kim, Sang-Rok Jeon, Eui Kyu Chie, Kyubo Kim, Gyeong Hoon Kang, Sae-Won Han, Tae-You Kim, Seung-Yong Jeong, Kyu Joo Park & Hong-Gyun Wu. (2017) Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8+ Tumor-Infiltrating Lymphocytes Identified Patients With Poor Prognosis in Rectal Cancer: A Matched Comparison Analysis. International Journal of Radiation Oncology*Biology*Physics 99:5, pages 1216-1224.
Crossref
Crossref
Luca Antonioli, Sergey V. Novitskiy, Kris F. Sachsenmeier, Matteo Fornai, Corrado Blandizzi & György Haskó. (2017) Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discovery Today 22:11, pages 1686-1696.
Crossref
Crossref
Evert J Van Limbergen, Dirk K De Ruysscher, Veronica Olivo Pimentel, Damiënne Marcus, Maaike Berbee, Ann Hoeben, Nicolle Rekers, Jan Theys, Ala Yaromina, Ludwig J Dubois & Philippe Lambin. (2017) Combining radiotherapy with immunotherapy: the past, the present and the future. The British Journal of Radiology 90:1076, pages 20170157.
Crossref
Crossref
M Lupu-Plesu, A Claren, S Martial, P-D N'Diaye, K Lebrigand, N Pons, D Ambrosetti, I Peyrottes, J Feuillade, J Hérault, M Dufies, J Doyen & G Pagès. (2017) Effects of proton versus photon irradiation on (lymph)angiogenic, inflammatory, proliferative and anti-tumor immune responses in head and neck squamous cell carcinoma. Oncogenesis 6:7, pages e354-e354.
Crossref
Crossref
Ralph R. Weichselbaum, Hua Liang, Liufu Deng & Yang-Xin Fu. (2017) Radiotherapy and immunotherapy: a beneficial liaison?. Nature Reviews Clinical Oncology 14:6, pages 365-379.
Crossref
Crossref
Wencheng Zhang, Qingsong Pang, Xiaodong Zhang, Cihui Yan, Qifeng Wang, Jinsong Yang, Shufei Yu, Xiao Liu, Yi Pan, Zhiyong Yuan, Ping Wang & Zefen Xiao. (2017) Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. Cancer Science 108:4, pages 590-597.
Crossref
Crossref
Jing Zhao, Peng Zhang, Jianhua Wang, Qingsong Xi, Xueqi Zhao, Minghua Ji & Guangyuan Hu. (2017) Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. Medicine 96:7, pages e6102.
Crossref
Crossref
F. Eckert, U.S. Gaipl, G. Niedermann, M. Hettich, K. Schilbach, S.M. Huber & D. Zips. (2017) Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation. Clinical and Translational Radiation Oncology 2, pages 29-35.
Crossref
Crossref
Ruth J. Davis, Robert L. Ferris & Nicole C. Schmitt. (2016) Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations. Cancers of the Head & Neck 1:1.
Crossref
Crossref
Gregory S. Alexander, Joshua D. Palmer, Madalina Tuluc, Jianqing Lin, Adam P. Dicker, Voichita Bar-Ad, Larry A Harshyne, Jennifer Louie, Colette M. Shaw, D. Craig Hooper & Bo Lu. (2016) Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. Journal of Hematology & Oncology 9:1.
Crossref
Crossref
V?ronique Hofman, Marius Ilie, Elodie Long, Catherine Butori, Sandra Lassalle, Kevin Washetine, Salom? Lalve, Charles-Hugo Marquette, Jean-Charles Soria & Paul Hofman. (2016) Enjeux et limites actuelles de l??valuation du statut de PD-L1?par immunohistochimie sur des biopsies bronchiques. Bulletin du Cancer 103:4, pages 368-380.
Crossref
Crossref
Zhong-Yi Dong, Si-Pei Wu, Ri-Qiang Liao, Shu-Mei Huang & Yi-Long Wu. (2016) Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. Tumor Biology 37:4, pages 4251-4261.
Crossref
Crossref
Gaixia He, Henghui Zhang, Jinxue Zhou, Beibei Wang, Yanhui Chen, Yaxian Kong, Xingwang Xie, Xueyan Wang, Ran Fei, Lai Wei, Hongsong Chen & Hui Zeng. (2015) Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research 34:1.
Crossref
Crossref
Anja Derer, Lisa Deloch, Yvonne Rubner, Rainer Fietkau, Benjamin Frey & Udo S. Gaipl. (2015) Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications. Frontiers in Immunology 6.
Crossref
Crossref